tbuckley/cabot-search huggingface dataset:
Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck
Authors: N. Honoré, C. van Marcke, R. Galot, R. Helaers, J. Ambroise, A. van Maanen, A. Mendola, H. Dahou, E. Marbaix, P. Van Eeckhout, E. Longton, M. Magremanne, S. Schmitz, N. Limaye, J.-P. Machiels
Journal: Annals of Oncology (2023)

Forty to fifty percent of patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) relapse despite multimodal treatment. Circulating tumor DNA (ctDNA) has the potential to detect minimal residual disease (MRD) after curative-intent therapy and to identify earlier which patients will progress. We developed a tumor-agnostic plasma ctDNA assay to detect MRD in unselected LA SCCHN with the aim of predicting progression-free survival (PFS) and overall survival without the need for tumor sequencing.A 26-gene next-generation sequencing panel was constructed that included the most frequently mutated genes in SCCHN and two HPV-16 genes. MRD was assessed in each patient through an in-house informatic workflow informed by somatic mutations identified in the corresponding pre-treatment plasma sample. The presence of MRD was defined as the detection of ctDNA in one plasma sample collected within 1-12 weeks of the end of curative treatment. The primary endpoint was the PFS rate at 2 years. At least 32 patients were planned for inclusion with the hypothesis that PFS at 2 years was >80% in MRD-negative patients and <30% in MRD-positive patients (α = 0.05, β = 0.9).We sequenced DNA from 116 plasma samples derived from 53 LA SCCHN patients who underwent curative-intent treatment. ctDNA was detected in 41/53 (77%) patients in the pre-treatment samples. Out of these 41 patients, 17 (41%) were MRD positive after treatment. The 2-year PFS rate was 23.53% (9.9% to 55.4%) and 86.6% (73.4% to 100%) in MRD-positive and MRD-negative patients, respectively (P < 0.05). Median survival was 28.37 months (14.30 months-not estimable) for MRD-positive patients and was not reached for the MRD-negative cohort (P = 0.011).Our ctDNA assay detects MRD in LA SCCHN and predicts disease progression and survival without the need for tumor sequencing, making this approach easily applicable in daily practice.
More than just methylisothiazolinone: Retrospective analysis of patients with isothiazolinone allergy in North America, 2017-2020
Authors: Margo J. Reeder, Donglin Zhang, Srikanth R. Aravamuthan, Erin M. Warshaw, Joel G. DeKoven, Jonathan I. Silverberg, Brandon L. Adler, Amber R. Atwater, James S. Taylor, Marie-Claude Houle, Donald V. Belsito, Jiade Yu, Nina Botto, Christen M. Mowad, Cory A. Dunnick, Vincent A. DeLeo, Melanie D. Pratt
Journal: Journal of the American Academy of Dermatology (2023)
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
Authors: A. Prelaj, V. Miskovic, M. Zanitti, F. Trovo, C. Genova, G. Viscardi, S.E. Rebuzzi, L. Mazzeo, L. Provenzano, S. Kosta, M. Favali, A. Spagnoletti, L. Castelo-Branco, J. Dolezal, A.T. Pearson, G. Lo Russo, C. Proto, M. Ganzinelli, C. Giani, E. Ambrosini, S. Turajlic, L. Au, M. Koopman, S. Delaloge, J.N. Kather, F. de Braud, M.C. Garassino, G. Pentheroudakis, C. Spencer, A.L.G. Pedrocchi
Journal: Annals of Oncology (2023)
Association of Age and Sex With Use of Transcatheter Aortic Valve Replacement in France
Authors: Graeme Prosperi-Porta, Virginia Nguyen, Nadav Willner, Julien Dreyfus, Helene Eltchaninoff, Ian G. Burwash, Morgane Michel, Eric Durand, Martine Gilard, Christel Dindorf, Bernard Iung, Alain Cribier, Alec Vahanian, Karine Chevreul, David Messika-Zeitoun
Journal: Journal of the American College of Cardiology (2023)
Cardiac Reoperation or Transcatheter Mitral Valve Replacement for Patients With Failed Mitral Prostheses
Authors: Hiroki A. Ueyama, Yoshihisa Miyamoto, Atsuyuki Watanabe, Hiroshi Gotanda, Stamatios Lerakis, Azeem Latib, Tsuyoshi Kaneko, Toshiki Kuno, Yusuke Tsugawa
Journal: Journal of the American College of Cardiology (2023)
Comparison of Intravascular Imaging, Functional, or Angiographically Guided Coronary Intervention
Authors: Toshiki Kuno, Yuko Kiyohara, Akiko Maehara, Hiroki A. Ueyama, Polydoros N. Kampaktsis, Hisato Takagi, Roxana Mehran, Gregg W. Stone, Deepak L. Bhatt, Gary S. Mintz, Sripal Bangalore
Journal: Journal of the American College of Cardiology (2023)
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Authors: A. Passaro, J. Wang, Y. Wang, S.-H. Lee, B. Melosky, J.-Y. Shih, J. Wang, K. Azuma, O. Juan-Vidal, M. Cobo, E. Felip, N. Girard, A.B. Cortot, R. Califano, F. Cappuzzo, S. Owen, S. Popat, J.-L. Tan, J. Salinas, P. Tomasini, R.D. Gentzler, W.N. William, K.L. Reckamp, T. Takahashi, S. Ganguly, D.M. Kowalski, A. Bearz, M. MacKean, P. Barala, A.B. Bourla, A. Girvin, J. Greger, D. Millington, M. Withelder, J. Xie, T. Sun, S. Shah, B. Diorio, R.E. Knoblauch, J.M. Bauml, R.G. Campelo, B.C. Cho
Journal: Annals of Oncology (2023)

Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial.
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention
Authors: Hirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, Ko Yamamoto, Yuki Obayashi, Ryusuke Nishikawa, Kenji Ando, Koh Ono, Kazushige Kadota, Satoru Suwa, Itsuro Morishima, Ruka Yoshida, Yoshiki Hata, Masaharu Akao, Masahiro Yagi, Nobuhiro Suematsu, Yoshihiro Morino, Takafumi Yokomatsu, Itaru Takamisawa, Toshiyuki Noda, Masayuki Doi, Hideki Okayama, Yuichi Nakamura, Kiyoshi Hibi, Hiroki Sakamoto, Teruo Noguchi, Takeshi Kimura
Journal: Journal of the American College of Cardiology (2023)
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Authors: Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Louise Warren, Edyta Jaworska, Michele Bombardieri, Myles J Lewis, Frances Humby, Arthur G Pratt, Andrew Filer, Nagui Gendi, Alberto Cauli, Ernest Choy, Iain McInnes, Patrick Durez, Christopher J Edwards, Maya H Buch, Elisa Gremese, Peter C Taylor, Nora Ng, Juan D Cañete, Sabrina Raizada, Neil D McKay, Deepak Jadon, Pier Paolo Sainaghi, Richard Stratton, Michael R Ehrenstein, Pauline Ho, Joaquim P Pereira, Bhaskar Dasgupta, Claire Gorman, James Galloway, Hector Chinoy, Désirée van der Heijde, Peter Sasieni, Anne Barton, Costantino Pitzalis, Ahmed Zayat, Ana Rita Machado, Andrea Cuervo, Arti Mahto, Cankut Cubuk, Charlotte Rawlings, Chijioke Mosanya, Chris Buckley, Chris Holroyd, Debbie Maskall, Francesco Carlucci, Georgina Thorborn, Gina Tan, Gloria Lliso-Ribera, Hasan Rizvi, Joanna Peel, João Eurico Fonseca, John Isaacs, Julio Ramírez, Laurent Meric de Bellefon, Liliane Fossati-Jimak, Mary Githinji, Mattia Congia, Neal Millar, Nirupam Purkayastha, Raquel Celis, Rakhi Seth, Rebecca Hands-Greenwood, Robert Landewé, Simone Perniola, Stefano Alivernini, Stefano Marcia, Stefano Marini, Stephen Kelly, Vasco Romão
Journal: The Lancet Rheumatology (2023)

Despite highly effective targeted therapies for rheumatoid arthritis, about 40% of patients respond poorly, and predictive biomarkers for treatment choices are lacking. We did a biopsy-driven trial to compare the response to rituximab, etanercept, and tocilizumab in biologic-naive patients with rheumatoid arthritis stratified for synovial B cell status.
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
Authors: Oliver Distler, Yannick Allanore, Christopher P Denton, Masataka Kuwana, Marco Matucci-Cerinic, Janet E Pope, Tatsuya Atsumi, Radim Bečvář, László Czirják, Eric Hachulla, Tomonori Ishii, Osamu Ishikawa, Sindhu R Johnson, Ellen De Langhe, Chiara Stagnaro, Valeria Riccieri, Elena Schiopu, Richard M Silver, Vanessa Smith, Virginia Steen, Wendy Stevens, Gabriella Szücs, Marie-Elise Truchetet, Melanie Wosnitza, Kaisa Laapas, Frank Kramer, Dinesh Khanna
Journal: The Lancet Rheumatology (2023)
Patients With Hypertrophic Cardiomyopathy and Normal Genetic Investigations Have Few Affected Relatives
Authors: Søren K. Nielsen, Frederikke G. Hansen, Torsten B. Rasmussen, Thomas Fischer, Jens F. Lassen, Trine Madsen, Dorthe S. Møller, Ib C. Klausen, John B. Brodersen, Morten S.K. Jensen, Jens Mogensen
Journal: Journal of the American College of Cardiology (2023)
Cardiovascular Fellowship Training in Cardio-Obstetrics
Authors: Melinda B. Davis, Natalie A. Bello, Kathryn Berlacher, Colleen M. Harrington, Jeannette P. Lin, Kathryn J. Lindley, Lindsay G. Panah, Ki E. Park, Candice K. Silversides, Mary Norine Walsh, Gaby Weissman, Doreen DeFaria Yeh, Julie B. Damp
Journal: Journal of the American College of Cardiology (2023)
<i>Vital Signs: </i>Health Worker–Perceived Working Conditions and Symptoms of Poor Mental Health — Quality of Worklife Survey, United States, 2018–2022
Authors: Jeannie A. S. Nigam, R. Michael Barker, Thomas R. Cunningham, Naomi G. Swanson, L. Casey Chosewood
Journal: MMWR Morbidity and Mortality Weekly Report (2023)

Health workers faced overwhelming demands and experienced crisis levels of burnout before the COVID-19 pandemic; the pandemic presented unique challenges that further impaired their mental health.Data from the General Social Survey Quality of Worklife Module were analyzed to compare self-reported mental health symptoms among U.S. adult workers from 2018 (1,443 respondents, including 226 health workers) and 2022 (1,952, including 325 health workers). Logistic regression was used to examine associations between health workers' reported perceptions of working conditions and anxiety, depression, and burnout.From 2018 to 2022, health workers reported an increase of 1.2 days of poor mental health during the previous 30 days (from 3.3 days to 4.5 days); the percentage who reported feeling burnout very often (11.6% to 19.0%) increased. In 2022, health workers experienced a decrease in odds of burnout if they trusted management (odds ratio [OR] = 0.40), had supervisor help (OR = 0.26), had enough time to complete work (OR = 0.33), and felt that their workplace supported productivity (OR = 0.38), compared with those who did not. Harassment at work was associated with increased odds of anxiety (OR = 5.01), depression (OR = 3.38), and burnout (OR = 5.83).Health workers continued to face a mental health crisis in 2022. Positive working conditions were associated with less burnout and better mental health. CDC's National Institute for Occupational Safety and Health has developed a national campaign, Impact Wellbeing, to provide employers of health workers with resources to improve the mental health of these workers.
Elegy With the Source of My Insomnia
Authors: Nanki Hura
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mendelian randomization in hepatology: A review of principles, opportunities, and challenges
Authors: Yilin Song, Ting Ye, Lewis R. Roberts, Nicholas B. Larson, Stacey J. Winham
Journal: Hepatology (2023)

Mendelian randomization has become a popular tool to assess causal relationships using existing observational data. While randomized controlled trials are considered the gold standard for establishing causality between exposures and outcomes, it is not always feasible to conduct a trial. Mendelian randomization is a causal inference method that uses observational data to infer causal relationships by using genetic variation as a surrogate for the exposure of interest. Publications using the approach have increased dramatically in recent years, including in the field of hepatology. In this concise review, we describe the concepts, assumptions, and interpretation of Mendelian randomization as related to studies in hepatology. We focus on the strengths and weaknesses of the approach for a non-statistical audience, using an illustrative example to assess the causal relationship between body mass index and NAFLD.
Pregnancy Outcomes in Transgender People—Reply
Authors: Daphna Stroumsa, Halley Crissman, Michelle H. Moniz
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years
Authors: Michael J. Mack, Martin B. Leon, Vinod H. Thourani, Philippe Pibarot, Rebecca T. Hahn, Philippe Genereux, Susheel K. Kodali, Samir R. Kapadia, David J. Cohen, Stuart J. Pocock, Michael Lu, Roseann White, Molly Szerlip, Julien Ternacle, S. Chris Malaisrie, Howard C. Herrmann, Wilson Y. Szeto, Mark J. Russo, Vasilis Babaliaros, Craig R. Smith, Philipp Blanke, John G. Webb, Raj Makkar
Journal: New England Journal of Medicine (2023)

A previous analysis in this trial showed that among patients with severe, symptomatic aortic stenosis who were at low surgical risk, the rate of the composite end point of death, stroke, or rehospitalization at 1 year was significantly lower with transcatheter aortic-valve replacement (TAVR) than with surgical aortic-valve replacement. Longer-term outcomes are unknown.
An Important Tool to Understand Durable Medical Equipment and Supply Use in Children
Authors: Claudette O. Adegboro, Ryan J. Coller
Journal: JAMA Network Open (2023)

Arda Hotz, MD, MPH; Eli Sprecher, MD, MPP; Lucia Bastianelli, CRNP; Jonathan Rodean, MS; Isabel Stringfellow, BS; Elizabeth Barkoudah, MD; Laurie E. Cohen, MD; Carlos Estrada, MD, MBA; Robert Graham, MD; Jonathan Greenwood, PT, MS, DPT; Jennifer Kyle, RN, MA; Nina Mann, MD; Maria Pinkham, PT, DPT; Toni Solari, RD, LDN; Rachel Rosen, MD, MPH; Susan Saleeb, MD; Ankoor S. Shah, MD, PhD; Karen Watters, MB, BCh, BAO, MPH; Sarah Wells, MSN, RN, CPN; Jay G. Berry, MD, MPH
Resident regulatory T cells reflect the immune history of individual lymph nodes
Authors: Anne Kaminski, Fabian Tobias Hager, Lydia Kopplin, Fabio Ticconi, Andrea Leufgen, Emilia Vendelova, Lennart Rüttger, Georg Gasteiger, Vuk Cerovic, Wolfgang Kastenmüller, Oliver Pabst, Milas Ugur
Journal: Science Immunology (2023)

Regulatory T cells (Tregs) are present in lymphoid and nonlymphoid tissues where they restrict immune activation, prevent autoimmunity, and regulate inflammation. Tregs in nonlymphoid tissues are typically resident, whereas those in lymph nodes (LNs) are considered to recirculate. However, Tregs in LNs are not a homogenous population, and circulation kinetics of different Treg subsets are poorly characterized. Furthermore, whether Tregs can acquire memory T cell properties and persist for extended periods after their activation in LNs is unclear. Here, we used in situ labeling with a stabilized photoconvertible protein to uncover turnover rates of Tregs in LNs in vivo. We found that, whereas most Tregs in LNs recirculate, 10 to 20% are memory-like resident cells that remain in their respective LNs for weeks to months. Single-cell RNA sequencing revealed that LN-resident cells are a functionally and ontogenetically heterogeneous population and share the same core residency gene signature with conventional CD4+ and CD8+ T cells. Resident cells in LNs did not actively proliferate and did not require continuous T cell receptor (TCR) signaling for their residency. However, resident and circulating Tregs had distinct TCR repertoires, and each LN contained exclusive clonal subpopulations of resident Tregs. Our results demonstrate that, similar to conventional T cells, Tregs can form resident memory-like populations in LNs after adaptive immune responses. Specific and local suppression of immune responses by resident Tregs in draining LNs might provide previously unidentified therapeutic opportunities for the treatment of local chronic inflammatory conditions.
Cell State of Origin Impacts Development of Distinct Endometriosis-Related Ovarian Carcinoma Histotypes
Authors: Ian Beddows, Huihui Fan, Karolin Heinze, Benjamin K. Johnson, Anna Leonova, Janine Senz, Svetlana Djirackor, Kathleen R. Cho, Celeste Leigh Pearce, David G. Huntsman, Michael S. Anglesio, Hui Shen
Journal: Cancer Research (2023)

Abstract Clear cell ovarian carcinoma (CCOC) and endometrioid ovarian carcinoma (ENOC) are ovarian carcinoma histotypes, which are both thought to arise from ectopic endometrial (or endometrial-like) cells through an endometriosis intermediate. How the same cell type of origin gives rise to two morphologically and biologically different histotypes has been perplexing, particularly given that recurrent genetic mutations are common to both and present in nonmalignant precursors. We used RNA transcription analysis to show that the expression profiles of CCOC and ENOC resemble those of normal endometrium at secretory and proliferative phases of the menstrual cycle, respectively. DNA methylation at the promoter of the estrogen receptor (ER) gene (ESR1) was enriched in CCOC, which could potentially lock the cells in the secretory state. Compared with normal secretory-type endometrium, CCOC was further defined by increased expression of cysteine and glutathione synthesis pathway genes and downregulation of the iron antiporter, suggesting iron addiction and highlighting ferroptosis as a potential therapeutic target. Overall, these findings suggest that while CCOC and ENOC arise from the same cell type, these histotypes likely originate from different cell states. This “cell state of origin” model may help to explain the presence of histologic and molecular cancer subtypes arising in other organs. Significance: Two cancer histotypes diverge from a common cell of origin epigenetically locked in different cell states, highlighting the importance of considering cell state to better understand the cell of origin of cancer.
Pregnancy Outcomes in Transgender People
Authors: Si-Kei Chiu
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
Authors: Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Julia A. Sobotka, Precious Uju, Jenna Eagles, Stephanie Pedersen, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Lawrence E. Heisler, Richard Jovelin, Bernard Lam, Beatriz E. Lujan Toro, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, Carina Man, Anna Goldenberg, Wei Xu, Patrick Veit-Haibach, Andrea S. Doria, David Malkin, Raymond H. Kim, Trevor J. Pugh
Journal: Cancer Discovery (2023)

People with Li-Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multimodal liquid biopsy assay that integrates a targeted gene panel, shallow whole-genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 LFS patients. Multimodal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis and was able to detect cancer-associated signal(s) in carriers prior to diagnosis with conventional screening (positive predictive value = 67.6%, negative predictive value = 96.5%). Although adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with LFS. By utilizing an integrated cell-free DNA approach, liquid biopsy shows earlier detection of cancer in patients with LFS compared with current clinical surveillance methods such as imaging. Liquid biopsy provides improved accessibility and sensitivity, complementing current clinical surveillance methods to provide better care for these patients. See related commentary by Latham et al., p. 23. This article is featured in Selected Articles from This Issue, p. 5.